Panacea Biotec Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec reported audited FY2026 results. Standalone total income rose 32.2% to ₹43,149 lakh (vs ₹32,647 lakh in FY25), driven by Vaccines segment growth. However, standalone net loss widened to ₹2,988 lakh (vs ₹1,523 lakh loss in FY25), reflecting higher raw material costs and finance expenses. Consolidated total income grew 14.4% to ₹65,667 lakh, with consolidated net loss improving to ₹716 lakh (vs ₹872 lakh). The company skipped dividend on equity and preference shares due to losses. Auditors issued an unmodified opinion. The Board also appointed Mr. Rajinder Singh Manku as non-executive independent director for 5 years from July 1, 2026. Key highlights include completion of DengiAll® Phase-III clinical trial enrollment and recognition of ₹1,950 lakh in exceptional income from Apotex settlement and deferred brand sale consideration.
Revenue is growing strongly, but persistent losses and negative standalone operating cash flow of ₹4,015 lakh raise concerns about near-term profitability and liquidity. The going concern note on the standalone entity (negative retained earnings of ₹21,782 lakh) adds risk, though the consolidated group remains financially stronger.